Nationwide Children’s Hospital

Cell and gene therapy companies raised $10.7bn during the first half of 2020, exceeding the $9.8bn full-year total that the regenerative medicine sector raised in 2019. Venture capital financings in t

Sarepta Therapeutics Inc. CEO Doug Ingraham said that out-licensing ex-US rights to its Duchenne muscular dystrophy (DMD) gene therapy SRP-9001 to Roche eventually will bring the company more than

Novartis AG said when it disclosed that preclinical safety data for Zolgensma were manipulated in the biologic license application for the gene therapy that the company would be "exiting" employees i

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. OncoSec